Emgality (galcanezumab) is a once-monthly subcutaneous injection – it binds to the calcitonin gene-related peptide (CGRP), which is believed to play a role in migraine attacks.
The NICE recommendation is based on results from a number of clinical trials which investigated Emgality’s efficacy and safety, including the CONQUER, REGAIN, EVOLVE-1 and EVOLVE-2 trials.
The EVOLVE-1 and EVOLVE-2 trials, which involved over 1,700 patients who had migraines between four and 14 days a month, demonstrated that those who received Emgality had four or five fewer days with migraines per month…
